Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 20,000,000
    Countries
    Sector(s)
    The Netherlands : € 20,000,000
    Services : € 20,000,000
    Signature date(s)
    28/06/2019 : € 20,000,000

    Summary sheet

    Release date
    10 July 2019
    Status
    Reference
    Signed | 28/06/2019
    20170706
    Project name
    Promoter - financial intermediary
    ISA PHARMACEUTICALS (IDFF)
    ISA PHARMACEUTICALS BV
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 20 million
    EUR 48 million
    Location
    Sector(s)
    • Services - Professional, scientific and technical activities
    Description
    Objectives

    The project supports the company's research and development investments to complete the late stage development (clinical, regulatory, and manufacturing) of ISA101b - a synthetic long peptide (SLP) targeting human papilloma viruses (HPV) - in two HPV-induced therapeutic areas i.e. cervical, head and neck cancer.

    The proceeds from the EIB loan will be used to co-finance the project, which - if successful - will create new treatment options for patients suffering from these diseases, thereby addressing a substantial unmet medical need, and saving and improving the lives of thousands of patients. The project will also contribute to the growth of a European biopharmaceutical company and the creation of new high-skilled jobs.

    Environmental aspects
    Procurement

    The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC. However, full environmental details verified during the appraisal are aligned with best practices.

    The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions.

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications